

OPEXA THERAPEUTICS, INC.

FORM 8-K (Current report filing)

Filed 02/18/05 for the Period Ending 02/15/05

Address	2635 TECHNOLOGY FOREST BLVD. THE WOODLANDS, TX 77381
Telephone	(281) 272-9331
CIK	0001069308
Symbol	OPXA
SIC Code	2834 - Pharmaceutical Preparations
Fiscal Year	12/31

UNITED STATES
SECURITIES EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of

The Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): February 15, 2005

PHARMAFRONTIERS CORP.

(Exact name of registrant as specified in its charter)

Texas	000-25513	760333165
-----	-----	-----
(State of organization)	(Commission File Number)	(IRS Employer Identification No.)
2408 Timberloch Place Suite B-7 The Woodlands, Texas		77380
-----		-----
(Address of principal executive offices)		(Zip Code)

Registrant's Telephone Number, including area code: (281) 272-9331

Former name or former address, if changed since last report: Not Applicable

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Item 5.02. Departure of Directors or Principal Officers; Election of Directors; Appointment of Principal Officers.

On February 15, 2005, PharmaFrontiers Corp. (the "Company") announced the resignation of Jeffrey Adduci as a director of the Board of Directors ("Board") for personal reasons, effective immediately. Mr. Adduci served on the Board since March 2004. Mr. Adduci also resigned his position as a member of the compensation committee. Mr. Adduci had no disputes or differences in opinion on any matter relating to the Company's operations, policies or practices.

Item 9.01. Financial Statements and Exhibit

(c) Exhibits

The following is to be filed as part of this 8-K:

EXHIBIT NO. -----	IDENTIFICATION OF EXHIBIT -----
99.1	Exhibit "A" - Resignation of Jeffrey Adduci dated February 15, 2005

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

PHARMAFRONTIERS CORP.

By: /s/ David B. McWilliams

David B. McWilliams, Chief Executive Officer

DATE: February 18, 2005

EXHIBIT INDEX

Exhibit No. Description

99.1 Exhibit "A" - Resignation of Jeffrey Adduci dated February 15, 2005

To the Board of Directors of Pharma Frontiers Corp. (the "Company"):

Effective February 15, 2005, I, Jeffrey Adduci, hereby resign as director of Pharma Frontiers Corp. and resign as a member of the compensation committee of the Company. I am resigning solely for personal reasons and have no disputes or differences in opinion on any matter relating to the Company's operations, policies or practices.

I have been provided with a copy of the Form 8-K disclosing my resignation and I have no disagreement with any statements made in that disclosure.

/s/ Jeffrey Adduci

Jeffrey Adduci